Christopher G Earnhart Selected Research

Therapeutics

3/2022

A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christopher G Earnhart Research Topics

Disease

7	Infections 01/2022 - 12/2005
5	Lyme Disease (Disease, Lyme) 01/2020 - 12/2005
4	COVID-19 05/2024 - 01/2022
2	Relapsing Fever 08/2014 - 07/2011
1	Botulism 01/2019

Drug/Important Bio-Agent (IBA)

8	1-oleoyl-2-stearoylphosphatidylcholineIBA 01/2020 - 12/2005
6	EpitopesIBA 01/2022 - 12/2005
4	Monoclonal AntibodiesIBA 05/2024 - 01/2019
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2016
4	OspC proteinIBA 01/2019 - 12/2005
3	AntibodiesIBA 04/2023 - 01/2022
3	VaccinesIBA 01/2017 - 12/2005
2	Lipoproteins (Lipoprotein)IBA 01/2017 - 06/2011
2	Virulence Factors (Pathogenicity Factors)IBA 08/2014 - 12/2005
1	cilgavimab and tixagevimab drug combinationIBA 05/2024
1	COV2-2130IBA 04/2023
1	cilgavimabIBA 04/2023
1	Neutralizing AntibodiesIBA 03/2022
1	ADM03820IBA 03/2022
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2020
1	AerosolsIBA 01/2019
1	AntigensIBA 01/2017
1	OspA proteinIBA 01/2017
1	Subunit VaccinesIBA 01/2017
1	Immunoglobulin G (IgG)IBA 12/2016
1	Green Fluorescent ProteinsIBA 07/2011
1	LigandsIBA 04/2010

Therapy/Procedure

1	Therapeutics 03/2022